Typical Challenges
Typically, we are asked to join an existing program which is underperforming in the already initiated sites. Our typical response is to shorten timelines to clinical trial authorization in our countries by a staggered effort based on extra-time and over-time of our specialists.
Else, we are frequently asked to do a one, two, three country exploratory Phase II (e.g. dose-finding) in a very short amount of time, to reduce time-lines to start phase III globally.
We specialize in hard to find patients and pediatric studies.